We observed that all CRISPR/Cas treatment modalities targeting the BCR/ABL1 fusion gene were beneficial with respect to the tumor volume, as assessed 30 days post tumor electroporation (Fig. 4f, Supplementary Fig. 22). The gene discussed is BCR; the disease is neoplasm.